Novo Nordisk will bring Wegovy to the UK in tablet form, marking the first time the blockbuster weight-loss drug becomes available as a daily pill rather than a weekly injection. The pharmaceutical giant frames the oral formulation as a convenience play for patients who prefer tablets to needles.
Wegovy, which contains semaglutide, has become a global phenomenon since its approval for chronic weight management. The drug commands premium pricing and drives significant revenue for Novo Nordisk. Weekly injections remain the standard delivery method worldwide, but the pill format addresses a real barrier for injection-averse patients.
The UK move arrives as Novo Nordisk faces intensifying competition. Eli Lilly's tirzepatide, marketed as Zepbound in weight loss and Mounjaro for diabetes, has gained traction as an alternative GLP-1 agonist. Both drugs capture demand from patients seeking pharmaceutical weight-loss solutions, and both companies race to expand access through multiple delivery mechanisms.
The tablet's arrival in the UK reflects broader market dynamics. Demand for weight-loss medications continues accelerating on social media hype, celebrity endorsement, and genuine clinical efficacy. Supply constraints plagued early rollout phases, but manufacturers now scale production to meet surging prescription volumes. The shift toward oral formulations also signals confidence in long-term demand and market maturation.
Novo Nordisk has not announced pricing for the UK tablet or a specific launch date, leaving questions about affordability relative to injections. NHS coverage decisions will shape real-world uptake. The pill format could unlock new patient segments while retaining existing injection users who remain satisfied with their current regimen.
This expansion cements the weight-loss drug category's staying power and signals pharmaceutical investment will continue flowing toward metabolic health treatments. Novo Nordisk and Eli Lilly now compete not just on efficacy but on delivery convenience and market penetration.